1. Chordia Therapeutics Inc.
  2. News
サブ-ナビゲーション
  • Company
  • Science
  • 現在位置:News
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

News

  • Sep 15, 2023 Selected for the latest edition of "100 Amazing Venture Businesses" in 2023 pdf （184KB）
  • Sep 15, 2023 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023 pdf （267KB）
  • Jun 01, 2023 Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf （166KB）
  • May 17, 2023 Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs pdf （147KB）
  • Feb 17, 2023 Initiated Phase 1/2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf （301KB）
  • Feb 16, 2023 Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor, According to License Agreement with Ono Pharmaceutical pdf （238KB）
  • Dec 12, 2022 Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting. pdf （284KB）
  • Nov 21, 2022 Published 5th Financial Report pdf （496KB）
  • Oct 03, 2022 Chordia Therapeutics Director and Statutory Auditor Appointments pdf （263KB）
  • Sep 08, 2022 Chordia Named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022 pdf （270KB）
  • Aug 29, 2022 Chordia’s Licensee Ono Pharmaceutical Co., Ltd. Initiated a Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S. pdf （281KB）
  • Jun 07, 2022 Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting pdf （304KB）
  • Jun 07, 2022 Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd. pdf （216KB）
  • May 19, 2022 Concludes Basic Agreement on Business Tie Up with MEDIPAL HOLDINGS CORPORATION pdf （232KB）
  • May 19, 2022 Raises Approximately 4 Billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 Billion JPY pdf （215KB）
  • May 16, 2022 Featured as a Cover Story in Startup City Magazine’s “Top 10 Japanese Startups 2022” pdf （2,325KB）
  • Apr 07, 2022 Nominated as a Finalist of the Informa Pharma Intelligence Awards Japan 2022 pdf （302KB）
  • Dec 03, 2021 Published 4th financial report pdf （660KB）
  • Sep 24, 2021 Assignment of Statutory Auditor pdf （92KB）
  • Mar 03, 2021 Interview with CEO Miyake Published in Scrip
  • Feb 04, 2021 Interview with CSO Morishita Published in AnswersNews
  • Dec 15, 2020 Notice of License Agreement pdf （121KB）
  • Oct 25, 2019 Chordia Therapeutics Announced the Appointment of CMO & CSO pdf （181KB）
  • Mar 29, 2019 Chordia Therapeutics Raises Around $27 Million in Series B Financing pdf （212KB）
  • Jan 10, 2019 Published Our Article in Forbes JAPAN
  • Oct 12, 2018 1st Results Presentation of the AMED ACT-M pdf （846KB）
  • Nov 30, 2017 Chordia Therapeutics Raises Around $11 Million in Series A Financing pdf （562KB）
  • Nov 22, 2017 Launch of Chordia Therapeutics pdf （562KB）

VIEW ALL

    マルチ3はありません

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box